Last Patient Last Visit Completed in Innovation Pharmaceuticals’ Phase 2 Clinical Trial of Brilacidin for COVID-19; Trial Database Undergoing Review in Preparation for Database Lock
12. August 2021 09:00 ET
|
Innovation Pharmaceuticals Inc.
WAKEFIELD, Mass., Aug. 12, 2021 (GLOBE NEWSWIRE) -- Innovation Pharmaceuticals (OTCQB:IPIX) (“the Company”), a clinical stage biopharmaceutical company, today provided additional information...
Innovation Pharmaceuticals Provides Update on Brilacidin Antiviral Research
02. August 2021 07:00 ET
|
Innovation Pharmaceuticals Inc.
WAKEFIELD, Mass., Aug. 02, 2021 (GLOBE NEWSWIRE) -- Innovation Pharmaceuticals (OTCQB:IPIX) (“the Company”), a clinical stage biopharmaceutical company, today provided an update on ongoing antiviral...
Innovation Pharmaceuticals Announces New In Vitro Data Supporting Brilacidin’s Broad-Spectrum Antiviral Potential Presented at the American Society of Virology’s Annual Meeting
22. Juli 2021 09:00 ET
|
Innovation Pharmaceuticals Inc.
Brilacidin showed potent inhibition in multiple human cell lines and in different strains of alphaviruses and bunyaviruses, building on earlier antiviral work in coronavirusesThese data collectively...
Innovation Pharma Announces New Brilacidin Antiviral Research on Non-SARS-CoV-2 Endemic Viral Diseases to be Presented at the 2021 Military Health System Research Symposium
18. Juni 2021 09:30 ET
|
Innovation Pharmaceuticals Inc.
Presentation to be part of the “Development of New Front Line Therapies to Prevent and Treat Non-SARS-CoV-2 Endemic Viral Diseases” Breakout Session WAKEFIELD, Mass., June 18, 2021 (GLOBE NEWSWIRE)...
Innovation Pharma Completes Enrollment in Phase 2 Clinical Trial for COVID-19
03. Juni 2021 07:00 ET
|
Innovation Pharmaceuticals Inc.
WAKEFIELD, Mass., June 03, 2021 (GLOBE NEWSWIRE) -- Innovation Pharmaceuticals (OTCQB:IPIX) (“the Company”), a clinical stage biopharmaceutical company, announced today that it has achieved full...
Patient Enrollment Reaches 90 Percent in Innovation Pharmaceuticals Phase 2 Clinical Trial of Brilacidin for COVID-19
27. Mai 2021 10:00 ET
|
Innovation Pharmaceuticals Inc.
WAKEFIELD, Mass., May 27, 2021 (GLOBE NEWSWIRE) -- Innovation Pharmaceuticals (OTCQB:IPIX) (“the Company”), a clinical stage biopharmaceutical company, today announces that patient enrollment in the...
Innovation Pharma Files Form 10-Q; Patient Enrollment in Phase 2 Clinical Trial of Brilacidin for COVID-19 Tops 70 Percent
13. Mai 2021 08:00 ET
|
Innovation Pharmaceuticals Inc.
WAKEFIELD, Mass., May 13, 2021 (GLOBE NEWSWIRE) -- Innovation Pharmaceuticals (OTCQB:IPIX) (“the Company”), a clinical stage biopharmaceutical company, today announces the filing of its SEC Form...
Innovation Pharma Surpasses 50 Percent Enrollment in Phase 2 Clinical Trial of Brilacidin for COVID-19
28. April 2021 08:00 ET
|
Innovation Pharmaceuticals Inc.
>60 patients have been randomized in the Company’s ~120-patient Phase 2 COVID-19 clinical trialWith COVID-19 cases rising worldwide as the coronavirus continues to mutate, the need is greater than...
Innovation Pharma’s Broad Spectrum Antiviral Drug Candidate Brilacidin Highlighted in Biodefense and Infectious Diseases COVID-19 Presentation
14. April 2021 09:30 ET
|
Innovation Pharmaceuticals Inc.
WAKEFIELD, Mass., April 14, 2021 (GLOBE NEWSWIRE) -- Innovation Pharmaceuticals (OTCQB:IPIX) (“the Company”), a clinical stage biopharmaceutical company, today announced that Brilacidin, the...
Innovation Pharma Announces Brilacidin Abstract Accepted for Oral Presentation at the American Society for Virology’s Annual Meeting
07. April 2021 09:30 ET
|
Innovation Pharmaceuticals Inc.
Growing body of in vitro data support Brilacidin’s potential as a broad-spectrum inhibitor of virusesBrilacidin is currently undergoing Phase 2 clinical testing against COVID-19 in hospitalized...